Finerenone (Kerendia): nsMRA for DKD & HFpEF Fibrosis
Bayer's Finerenone (Kerendia): 3rd-gen nonsteroidal selective MRA. FIDELIO-DKD renal HR 0.82; FINEARTS-HF HF+CV death -16%. FDA 2021 (DKD), 2025 (HFpEF).
Introduction: Beyond RAAS — Controlling MR-Driven Fibrosis
ACE inhibitors and ARBs have been the DKD standard for decades, yet MR pathway reactivation via aldosterone breakthrough left a residual risk. Steroidal MRAs (spironolactone, eplerenone) were constrained by hyperkalemia, gynecomastia, and sex-hormone side effects. Bayer's Finerenone (BAY 94-8862 / Kerendia) closed this gap as a third-generation nonsteroidal selective MRA (nsMRA), improving renal and cardiovascular outcomes across >30,000 patients in FIDELIO-DKD, FIGARO-DKD, and FINEARTS-HF[1][2][3]. This article reviews MR-driven fibrosis biology, the three pivotal Phase 3 trials, preclinical evidence, and competitive positioning based on public sources.
1. Compound Profile
| Item | Detail |
|---|---|
| Generic name | Finerenone |
| Brand name | Kerendia |
| Development code | BAY 94-8862 |
| Sponsor | Bayer |
| Modality | Oral small-molecule, third-gen nonsteroidal selective MRA (nsMRA) |
| MR affinity | Kd ≈ 1.5 nM (aldosterone-comparable); MR/GR/AR/PR selectivity >500× |
| Dose | 10 or 20 mg PO QD (eGFR-adjusted) |
| Indications | T2DM-associated CKD; HFpEF (LVEF ≥40%) |
| Approvals | FDA 2021-07-09 (DKD), EMA 2022-02 (DKD), PMDA 2022-03 (DKD), FDA 2025-07-14 (HFpEF expansion), EC 2026-03-26 (HFpEF EU expansion), MHRA 2026-04-13 (HFpEF UK expansion) |
The nonsteroidal scaffold avoids sex-hormone side effects while delivering balanced renal-cardiac tissue distribution and lower fluid retention risk than steroidal MRAs.
For researchers tracking fibrosis & inflammation R&D
FDA approval alerts, trial readouts, preclinical model selection, and assay optimization — curated signal for bench-to-pipeline readers. 2 emails/month max.
2. MR Hyperactivation in Fibrosis & Inflammation
The mineralocorticoid receptor is a ligand-activated nuclear receptor expressed in mesangial cells, podocytes, endothelium, and cardiac fibroblasts. In T2DM and chronic heart failure, sustained RAAS activation drives MR-dependent induction of TGF-β1, PAI-1, MCP-1, and NADPH oxidase (Nox2/4), accelerating glomerular basement membrane damage, tubulointerstitial fibrosis, endothelial dysfunction, and cardiac fibrosis[4].
Because RAAS inhibitors alone do not durably suppress the MR axis (aldosterone breakthrough), direct MR blockade provides a second tier of cardio-renal protection.
3. Mechanism: Why nsMRA Differs from Steroidal MRAs
- Spironolactone: steroidal backbone, low MR/GR/AR/PR selectivity, partial agonist activity — weakly activates nuclear MR even without aldosterone.
- Eplerenone: steroidal, improved MR selectivity (~22×), but affinity 1/50 of Finerenone.
- Finerenone: nonsteroidal, blocks post-binding MR conformational change, suppressing coactivator recruitment — a full antagonist.
Tissue distribution is more balanced for Finerenone, reducing fluid retention, hyperkalemia, and sex-hormone effects while preserving efficacy on cardio-renal endpoints.
4. Clinical Evidence: Three Pivotal Phase 3 Trials
4-1. FIDELIO-DKD (NCT02540993, n=5,734)[1]
- Population: T2DM-CKD (UACR 30–5000 mg/g, eGFR 25–75)
- Primary endpoint (renal composite): kidney failure, sustained ≥40% eGFR decline, renal death
- Result: Finerenone 17.8% vs placebo 21.1%, HR 0.82 (95% CI 0.73–0.93), p=0.001
- Key secondary (CV composite): HR 0.86, p=0.03
- Median follow-up 2.6 years. Bakris GL, Agarwal R, et al., N Engl J Med 2020 (PMID 33264825)
4-2. FIGARO-DKD (NCT02545049, n=7,437)[2]
- Population: milder CKD with high CV risk
- Primary (CV composite): CV death, non-fatal MI, non-fatal stroke, HF hospitalization
- Result: Finerenone 12.4% vs placebo 14.2%, HR 0.87, p=0.03; HF hospitalization HR 0.71
- Pitt B, et al., N Engl J Med 2021
4-3. FIDELITY Pooled Analysis (n=13,026)
- Renal composite HR 0.80, p<0.001; CV composite 14% relative risk reduction. Eur Heart J 2022 (PMID 35023547)
4-4. FINEARTS-HF (NCT04435626, n=6,016)[3]
- Population: HFpEF/HFmrEF (LVEF ≥40%, NYHA II–IV)
- Primary: HF worsening events + CV death composite
- Result: 16% relative risk reduction; HF hospitalization −18%. Solomon SD, et al., N Engl J Med 2024 (PMID 39225278)
- Hyperkalemia 9.7% vs 4.2% (manageable with monitoring)
4-5. CONFIDENCE (Finerenone + Empagliflozin combination, Phase 2, n=818)[6]
- Design: T2D + CKD (UACR 100-5,000 mg/g, eGFR 30-90); Finerenone 10/20 mg + Empagliflozin 10 mg combination vs each monotherapy; 180-day UACR change
- Primary result (Apperloo E et al., NEJM June 5, 2025, NEJMoa2410659): combination UACR −52% from baseline; Empagliflozin alone −32%; Finerenone alone −29%. Combination delivered an additional benefit over each monotherapy (combo vs Empa: −29.5%, 95% CI −38.0 to −19.7, p<0.001 / combo vs Fine: −32.6%, 95% CI −40.7 to −23.4, p<0.001)
- Significance: provides the biological rationale for ADA 2026's recommendation of simultaneous nsMRA + SGLT2i initiation
4-6. FIND-CKD Phase 3 (NCT05047263, non-diabetic CKD)
- Bayer press release, March 16, 2026: FIND-CKD Phase 3 met its primary endpoint of eGFR slope (Finerenone vs placebo, up to 36 months, n≈1,584)
- Will form the basis of an indication expansion to non-diabetic CKD
5. Preclinical Fibrosis Evidence
- DOCA-salt rats: dose-dependent reduction in proteinuria, glomerular/tubular/vascular injury, and Sirius red collagen. Superior antifibrotic effect vs eplerenone[5].
- 5/6 nephrectomy: suppression of interstitial fibrosis (α-SMA⁺ myofibroblasts, collagen deposition); improved LV diastolic function; enhanced eNOS phosphorylation.
- UUO model: collagen deposition −34%, fibroblast accumulation −31%.
- Post-MI cardiac remodeling: reduced fibrosis score and LV remodeling.
Pair with UUO model implementation and hydroxyproline quantification to track renal/cardiac fibrosis endpoints consistently.
6. Competitive Landscape
| Agent | Class | Status | Comment |
|---|---|---|---|
| Esaxerenone (Takeda) | nsMRA | Approved JP, ESAX-DN | Outcome trial scale far smaller |
| KBP-5074 / Ocedurenone | nsMRA | Phase 3 | Focused on resistant hypertension; CV/renal outcomes pending |
| Spironolactone | Steroidal MRA | Legacy standard | Side-effect profile inferior |
| SGLT2i (dapagliflozin, etc.) | — | Approved | Additive renal protection with Finerenone |
| GLP-1RA (semaglutide, etc.) | — | Approved | Post-FLOW combination becoming standard |
Finerenone is the fourth pillar alongside RAAS inhibition + SGLT2i + GLP-1RA in DKD management.
7. Practical Considerations
- Hyperkalemia monitoring at initiation and titration is mandatory
- eGFR threshold: new initiation not recommended below eGFR 25
- Combination safety: SGLT2i co-administration can mitigate hyperkalemia risk via enhanced K⁺ excretion
8. Points to Watch
- HFpEF uptake post FDA 2025-07, EC 2026-03, MHRA 2026-04 HFpEF label expansion
- Non-diabetic CKD expansion: FIND-CKD Phase 3 met its eGFR slope primary endpoint in March 2026 (Bayer 2026-03-16 PR), enabling an sNDA for indication expansion
- Combination with IgAN/FSGS agents: Sparsentan, Atrasentan
- Next-gen nsMRAs (KBP-5074) competitive dynamics
- Biomarker-guided dosing: UACR, NT-proBNP, galectin-3
References
1. Bakris GL, et al. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med. 2020;383:2219-2229. PubMed 33264825 / ClinicalTrials.gov: NCT02540993
2. Pitt B, et al. Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes (FIGARO-DKD). N Engl J Med. 2021;385:2252-2263. PubMed 34449181 / ClinicalTrials.gov: NCT02545049
3. Solomon SD, et al. Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction (FINEARTS-HF). N Engl J Med. 2024;391(16):1475-1485. PubMed 39225278 / ClinicalTrials.gov: NCT04435626
4. Agarwal R, et al. Cardiovascular and kidney outcomes with finerenone: the FIDELITY pooled analysis. Eur Heart J. 2022;43:474-484. PubMed 35023547
5. Kolkhof P, et al. Finerenone, a Novel Selective Nonsteroidal Mineralocorticoid Receptor Antagonist Protects from Rat Cardiorenal Injury. J Cardiovasc Pharmacol. 2014;64:69-78. PubMed 24621652
6. Apperloo E, et al. Finerenone with Empagliflozin in Chronic Kidney Disease (CONFIDENCE). N Engl J Med. 2025;393(2):105-117. DOI 10.1056/NEJMoa2410659 (online June 5, 2025)
7. Bayer. FIND-CKD Phase 3 trial of Finerenone meets primary endpoint of slowing CKD progression. Press release, March 16, 2026. Bayer
8. Bayer. FDA Approves KERENDIA (finerenone) for Heart Failure with LVEF ≥40%. Press release, July 2025. Bayer